Domain licenses Parkinson's drug candidates to Merck Serono spinoff

01/24/2013 | Genetic Engineering & Biotechnology News

Merck Serono spinoff Prexton Therapeutics was given an exclusive option by Domain Therapeutics to advance through clinical development stage its metabotropic glutamate receptor 4-positive allosteric modulator drug candidates against Parkinson's disease. The chemical series emerged from joint work by Domain and Merck Serono.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA